The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Immunotherapy and beyond for lung cancer prevention
Jianjun Zhang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses innovative strategies in lung cancer interception during a session at the European Society for Medical Oncology (ESMO) 2024 Congress. The session explored lung cancer screening not only for heavy smokers but also for never-smokers and highlighted the role of biomarkers in enhancing screening protocols. Dr Zhang emphasizes the challenge of managing persistent lung nodules, which may represent precancerous lesions that complicate surgical or radiotherapeutic interventions. Dr Zhang highlights the importance of developing medical therapies to target these precancerous nodules, leveraging their unique molecular characteristics and preserved anti-tumor immunity. Immunotherapy is a primary focus, showing promising safety profiles and early evidence of efficacy in preventing the progression of precancerous nodules to invasive lung cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
